A citation-based method for searching scientific literature

Sirui Ma, Soumon Rudra, Jian L Campian, Sonika Dahiya, Gavin P Dunn, Tanner Johanns, Michael Goldstein, Albert H Kim, Jiayi Huang. Neurooncol Adv 2020
Times Cited: 11







List of co-cited articles
67 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
54

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
45

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Romain Appay, Caroline Dehais, Claude-Alain Maurage, Agusti Alentorn, Catherine Carpentier, Carole Colin, François Ducray, Fabienne Escande, Ahmed Idbaih, Aurélie Kamoun,[...]. Neuro Oncol 2019
41
36

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Gerald F Reis, Melike Pekmezci, Helen M Hansen, Terri Rice, Roxanne E Marshall, Annette M Molinaro, Joanna J Phillips, Hannes Vogel, John K Wiencke, Margaret R Wrensch,[...]. J Neuropathol Exp Neurol 2015
69
36

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
36

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
36

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.
David W Ellison, Cynthia Hawkins, David T W Jones, Arzu Onar-Thomas, Stefan M Pfister, Guido Reifenberger, David N Louis. Acta Neuropathol 2019
78
27

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori,[...]. Acta Neuropathol 2020
121
27

Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.
Alan Mackay, Anna Burford, Diana Carvalho, Elisa Izquierdo, Janat Fazal-Salom, Kathryn R Taylor, Lynn Bjerke, Matthew Clarke, Mara Vinci, Meera Nandhabalan,[...]. Cancer Cell 2017
353
27

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
27

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
297
27

Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Damian Stichel, Azadeh Ebrahimi, David Reuss, Daniel Schrimpf, Takahiro Ono, Mitsuaki Shirahata, Guido Reifenberger, Michael Weller, Daniel Hänggi, Wolfgang Wick,[...]. Acta Neuropathol 2018
80
27

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
27

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
114
27

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
27

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
27

Adult IDH wild-type lower-grade gliomas should be further stratified.
Abudumijit Aibaidula, Aden Ka-Yin Chan, Zhifeng Shi, Yanxi Li, Ruiqi Zhang, Rui Yang, Kay Ka-Wai Li, Nellie Yuk-Fei Chung, Yu Yao, Liangfu Zhou,[...]. Neuro Oncol 2017
111
27

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
990
27

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
656
27

Survival and long-term health and cognitive outcomes after low-grade glioma.
Gregory T Armstrong, Heather M Conklin, Sujuan Huang, Deokumar Srivastava, Robert Sanford, David W Ellison, Thomas E Merchant, Melissa M Hudson, Mary Ellen Hoehn, Leslie L Robison,[...]. Neuro Oncol 2011
118
18

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
18

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, Nicole Shonka, Sharon Gardner, Yoshie Umemura, Ashley Sumrall, Ziad Khatib, Sabine Mueller, Cassie Kline,[...]. J Neurooncol 2019
45
18

A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Ryusuke Hatae, Nobuhiro Hata, Satoshi O Suzuki, Koji Yoshimoto, Daisuke Kuga, Hideki Murata, Yojiro Akagi, Yuhei Sangatsuda, Toru Iwaki, Masahiro Mizoguchi,[...]. Neuropathology 2017
23
18

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Ibrahim Qaddoumi, Wilda Orisme, Ji Wen, Teresa Santiago, Kirti Gupta, James D Dalton, Bo Tang, Kelly Haupfear, Chandanamali Punchihewa, John Easton,[...]. Acta Neuropathol 2016
185
18

Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.
Andrey Korshunov, David Capper, David Reuss, Daniel Schrimpf, Marina Ryzhova, Volker Hovestadt, Dominik Sturm, Jochen Meyer, Chris Jones, Olga Zheludkova,[...]. Acta Neuropathol 2016
88
18

Myb proteins: angels and demons in normal and transformed cells.
Ye Zhou, Scott A Ness. Front Biosci (Landmark Ed) 2011
53
18

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
David T W Jones, Barbara Hutter, Natalie Jäger, Andrey Korshunov, Marcel Kool, Hans-Jörg Warnatz, Thomas Zichner, Sally R Lambert, Marina Ryzhova, Dong Anh Khuong Quang,[...]. Nat Genet 2013
464
18

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Quinn T Ostrom, Haley Gittleman, Gabrielle Truitt, Alexander Boscia, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2018
834
18

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Kenneth J Cohen, Ian F Pollack, Tianni Zhou, Allen Buxton, Emiko J Holmes, Peter C Burger, Daniel J Brat, Marc K Rosenblum, Ronald L Hamilton, Robert S Lavey,[...]. Neuro Oncol 2011
204
18

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Dong-Anh Khuong-Quang, Pawel Buczkowicz, Patricia Rakopoulos, Xiao-Yang Liu, Adam M Fontebasso, Eric Bouffet, Ute Bartels, Steffen Albrecht, Jeremy Schwartzentruber, Louis Letourneau,[...]. Acta Neuropathol 2012
541
18

A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration.
Jason Chiang, Julie H Harreld, Christopher L Tinkle, Daniel C Moreira, Xiaoyu Li, Sahaja Acharya, Ibrahim Qaddoumi, David W Ellison. Acta Neuropathol 2019
11
18

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
Lori A Ramkissoon, Peleg M Horowitz, Justin M Craig, Shakti H Ramkissoon, Benjamin E Rich, Steven E Schumacher, Aaron McKenna, Michael S Lawrence, Guillaume Bergthold, Priscilla K Brastianos,[...]. Proc Natl Acad Sci U S A 2013
126
18

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Anuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, Shengjie Wu, Theodore Nicolaides, Tina Young Poussaint, Jason Fangusaro, Joanna Phillips, Arie Perry, David Turner,[...]. Neuro Oncol 2017
134
18

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Alexandra M Miller, Ronak H Shah, Elena I Pentsova, Maryam Pourmaleki, Samuel Briggs, Natalie Distefano, Youyun Zheng, Anna Skakodub, Smrutiben A Mehta, Carl Campos,[...]. Nature 2019
171
18

MAPK pathway activation in pilocytic astrocytoma.
David T W Jones, Jan Gronych, Peter Lichter, Olaf Witt, Stefan M Pfister. Cell Mol Life Sci 2012
131
18

Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Koji Yoshimoto, Ryusuke Hatae, Yuhei Sangatsuda, Satoshi O Suzuki, Nobuhiro Hata, Yojiro Akagi, Daisuke Kuga, Murata Hideki, Koji Yamashita, Osamu Togao,[...]. Brain Tumor Pathol 2017
29
18

cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
David N Louis, Pieter Wesseling, Kenneth Aldape, Daniel J Brat, David Capper, Ian A Cree, Charles Eberhart, Dominique Figarella-Branger, Maryam Fouladi, Gregory N Fuller,[...]. Brain Pathol 2020
137
18

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Gang Wu, Alberto Broniscer, Troy A McEachron, Charles Lu, Barbara S Paugh, Jared Becksfort, Chunxu Qu, Li Ding, Robert Huether, Matthew Parker,[...]. Nat Genet 2012
952
18

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
Josefine Radke, Arend Koch, Fabienne Pritsch, Elisa Schumann, Martin Misch, Claudia Hempt, Klaus Lenz, Franziska Löbel, Fabienne Paschereit, Frank L Heppner,[...]. Acta Neuropathol Commun 2019
23
18

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
18

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
Alireza Mansouri, Laureen D Hachem, Sheila Mansouri, Farshad Nassiri, Normand J Laperriere, Daniel Xia, Neal I Lindeman, Patrick Y Wen, Arnab Chakravarti, Minesh P Mehta,[...]. Neuro Oncol 2019
68
18

Genetic and molecular epidemiology of adult diffuse glioma.
Annette M Molinaro, Jennie W Taylor, John K Wiencke, Margaret R Wrensch. Nat Rev Neurol 2019
149
18

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu,[...]. Acta Neuropathol Commun 2016
120
18

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Teri N Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A Butman, Kevin Camphausen,[...]. J Clin Oncol 2009
18

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
18

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Mitsuaki Shirahata, Takahiro Ono, Damian Stichel, Daniel Schrimpf, David E Reuss, Felix Sahm, Christian Koelsche, Annika Wefers, Annekathrin Reinhardt, Kristin Huang,[...]. Acta Neuropathol 2018
136
18

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
18

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Fan Wu, Guan-Zhang Li, Han-Jie Liu, Zheng Zhao, Rui-Chao Chai, Yu-Qing Liu, Hao-Yu Jiang, You Zhai, Yue-Mei Feng, Ren-Peng Li,[...]. J Pathol 2020
15
18

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
18

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
165
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.